BNIP3 and hepatocellular carcinoma: As mentioned before, the BNIP3-AMPK-ENO2 signaling pathway played a crucial role in sustaining the competitive advantage of LR HCC cells via regulating mitophagy-driven energy metabolism reprogramming, and co-treatment of BNIP3 inhibiter olomoucine substantially enhanced the antitumor effectiveness of lenvatinib 63.